BTIG Remains a Buy on Adicet Bio (ACET)

BTIG analyst Justin Zelin maintained a Buy rating on Adicet Bio (ACETResearch Report) on November 10 and set a price target of $34.00. The company’s shares closed last Friday at $21.27.

Zelin covers the Healthcare sector, focusing on stocks such as Poseida Therapeutics, Adicet Bio, and Precision BioSciences. According to TipRanks, Zelin has an average return of 0.7% and a 45.37% success rate on recommended stocks.

Adicet Bio has an analyst consensus of Strong Buy, with a price target consensus of $27.40, a 28.82% upside from current levels. In a report released on November 11, JMP Securities also reiterated a Buy rating on the stock with a $21.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

ACET market cap is currently $911.4M and has a P/E ratio of -14.60.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.

Read More on ACET:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More